The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...
Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...
the board of directors of Eli Lilly and Company (NYSE: LLY) approved a new $15 billion share repurchase program. The company's prior $5 billion share repurchase program was completed in the fourth ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Feb 5 (Reuters) - Eli Lilly (LLY.N), opens new tab investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug ...
8don MSN
Q4 2024 Management View CEO David Ricks highlighted a 45% revenue growth in Q4, with significant contributions from Mounjaro and Zepbound. He emphasized ongoing expansion in manufacturing to meet ...
He also noted operating income more than doubling to $5.6 billion, supported by strong new product sales. The company provided ... product differentiation. Eli Lilly ended 2024 on a strong note ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback